UA87515C2 - Фармацевтическая композиция толтеродина с пролонгированным высвобождением - Google Patents

Фармацевтическая композиция толтеродина с пролонгированным высвобождением

Info

Publication number
UA87515C2
UA87515C2 UAA200703260A UAA200703260A UA87515C2 UA 87515 C2 UA87515 C2 UA 87515C2 UA A200703260 A UAA200703260 A UA A200703260A UA A200703260 A UAA200703260 A UA A200703260A UA 87515 C2 UA87515 C2 UA 87515C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
tolterodine
sustained release
release pharmaceutical
composition
Prior art date
Application number
UAA200703260A
Other languages
English (en)
Ukrainian (uk)
Inventor
Адрейка Крамер
Роберт Писек
Тадея Райер
Original Assignee
Крка, Д.Д. Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34926332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA87515(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Крка, Д.Д. Ново Место filed Critical Крка, Д.Д. Ново Место
Publication of UA87515C2 publication Critical patent/UA87515C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к фармацевтической композиции с пролонгированным высвобождением, которая содержит толтеродин, преимущественно толтеродина тартрат, применения указанной композиции для приготовления лекарственного средства и способа получения такой фармацевтической композиции.
UAA200703260A 2004-08-27 2005-08-23 Фармацевтическая композиция толтеродина с пролонгированным высвобождением UA87515C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04020431A EP1629834A1 (en) 2004-08-27 2004-08-27 Sustained release pharmaceutical composition of tolterodine

Publications (1)

Publication Number Publication Date
UA87515C2 true UA87515C2 (ru) 2009-07-27

Family

ID=34926332

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200703260A UA87515C2 (ru) 2004-08-27 2005-08-23 Фармацевтическая композиция толтеродина с пролонгированным высвобождением

Country Status (7)

Country Link
EP (3) EP1629834A1 (ru)
AT (1) ATE505187T1 (ru)
DE (1) DE602005027469D1 (ru)
EA (1) EA200700484A1 (ru)
NO (1) NO20071299L (ru)
UA (1) UA87515C2 (ru)
WO (1) WO2006021425A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645940A1 (en) * 2006-03-21 2007-09-27 Teva Pharmaceutical Industries Ltd. Controlled release formulation of tolterodine
EP1839649A1 (en) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Coated formulations for tolterodine
KR100851033B1 (ko) * 2007-02-12 2008-08-12 명문제약주식회사 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
SG194809A1 (en) 2011-05-10 2013-12-30 Theravida Inc Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
CN103211784B (zh) * 2012-01-18 2017-07-11 北京天衡药物研究院有限公司 酒石酸托特罗定膜控缓释微丸胶囊
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
JP6841834B2 (ja) 2016-01-20 2021-03-10 テラヴィダ, インコーポレイテッドTheraVida, Inc. 多汗症の処置のための方法および組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE2061C1 (ru) † 1890-01-25
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6274171B1 (en) † 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9803871D0 (sv) † 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
EP2153825A1 (en) * 1998-08-27 2010-02-17 Pfizer Health AB Therapeutic formulation for administering tolterodine with controlled release
DE19901692C2 (de) † 1999-01-18 2002-06-20 Gruenenthal Gmbh Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes
SI1227806T1 (sl) † 1999-11-11 2005-12-31 Pfizer Health Ab Farmacevtska formulacija, ki vsebuje tolterodin in njena uporaba
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
IN191835B (ru) 2001-08-03 2004-01-10 Ranbaxy Lab Ltd
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20030152624A1 (en) * 2001-12-20 2003-08-14 Aldrich Dale S. Controlled release dosage form having improved drug release properties
KR100540035B1 (ko) † 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
CN1150160C (zh) 2002-04-29 2004-05-19 上海医药工业研究院 L－酒石酸托特罗定的合成方法
WO2004105735A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation

Also Published As

Publication number Publication date
EP1964553A1 (en) 2008-09-03
EP1629834A1 (en) 2006-03-01
EP1781275A1 (en) 2007-05-09
ATE505187T1 (de) 2011-04-15
EP1781275B2 (en) 2014-04-16
WO2006021425A1 (en) 2006-03-02
NO20071299L (no) 2007-05-29
EP1781275B1 (en) 2011-04-13
EA200700484A1 (ru) 2007-10-26
DE602005027469D1 (de) 2011-05-26

Similar Documents

Publication Publication Date Title
UA87515C2 (ru) Фармацевтическая композиция толтеродина с пролонгированным высвобождением
TW200716646A (en) (S)-N-methylnaltrexone
MX348525B (es) Proceso para producir poxvirus y composiciones de poxvirus.
MX2020008616A (es) Rocio de fentanilo sublingual.
TW200621765A (en) Substituted phenylaminothiazoles and their use
UA96449C2 (en) Stable laquinimod preparations
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
IL183360A (en) 12-aryl prostaglandin analogs, compositions comprising them and their use in the preparation of medicaments
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
DE502005005636D1 (en) Spirocyclische cyclohexan-derivate
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TW200612922A (en) Inhibitors of hsp90
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
UA103500C2 (ru) Сульфоксиминзамещенные анилинопиримидиновые производные как cdk-ингибиторы, их получение и применение как лекарственных средств
IL198845A (en) An extended-release peptide preparation, a process for its preparation and use for drug preparation
WO2011047837A3 (de) Schmelzgranuliertes cinacalcet
CR7271A (es) Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine
UA94042C2 (ru) Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса
GEP20115158B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction
MX2009005804A (es) Composicion farmaceutica de memantina.
TW200633717A (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
TW200706173A (en) Oral composition comprising carbamylating agent